Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy (REMAP-HCM)
Real-world Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy
The study will describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background/concomitant oHCM medications.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: First line of the email MUST contain NCT # and Site #.
Backup dei contatti dello studio
- Nome: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Numero di telefono: 855-907-3286
- Email: Clinical.Trials@bms.com
Luoghi di studio
-
-
-
Shanghai, Cina
- Fudan University Zhongshan Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study will include adults in China diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiated mavacamten treatment between 24 October 2024 and 31 March 2026.
Descrizione
Inclusion Criteria:
Participants must meet all of the following criteria to be included:
- Diagnosis: Have a documented diagnosis of obstructive hypertrophic cardiomyopathy (oHCM), identified by the corresponding International Classification of Diseases (ICD)-10 codes in the medical record system.
- Medication Exposure: Have a first-ever recorded prescription for Mavacamten within the Patient Identification Period (24 October 2024 to 31 March 2026). This date is defined as the Index Date.
- Age: Be ≥ 18 years of age at the Index Date.
- Treatment Continuity: Have at least two valid clinical records of any type (e.g., outpatient visit, inpatient encounter, prescription refill, laboratory test, or echocardiogram) after the Index Date.
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded:
(1) Prior Use of Study Drug: Have any documented history of Mavacamten use (based on medical history records, prescription records, or clinical notes) at any time prior to the Index Date.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: RETROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Category A1. Sustained Monotherapy
Participants who initiate mavacamten as monotherapy and remained on monotherapy throughout follow-up. |
As per product label |
|
Category A2. Treatment Intensification
Participants who initiate mavacamten monotherapy and subsequently added one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications during follow-up. |
As per product label |
|
Category B1. Stable Combination Therapy at Initiation
Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and remain on combination therapy throughout follow-up. |
As per product label |
|
Category B2. Treatment Simplification
Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and subsequently discontinued all background oHCM medications, resulting in mavacamten monotherapy. |
As per product label |
|
Category C. Complex/Unclassifiable
Participants whose treatment records indicate multiple treatment changes that could not be classified into the predefined treatment strategy groups. |
As per product label |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Number of participants in each study cohort
Lasso di tempo: Baseline and months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and months 1, 2, 3, 6, 9, 12 and 15
|
|
Absolute change (mmHg) from baseline in resting peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography
Lasso di tempo: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
|
Absolute change (mmHg) from baseline in post-Valsalva peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography
Lasso di tempo: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with at least 1-class improvement from baseline in New York Heart Association (NYHA) functional class
Lasso di tempo: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
|
|
New York Heart Association (NYHA) functional class classification as assessed by the treating physician
Lasso di tempo: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
|
|
Change from baseline in left atrial dimension (LAD) or left atrial volume index (LAVI) assessed by transthoracic echocardiography
Lasso di tempo: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
|
|
Change from baseline in interventricular septal thickness (IVST) assessed by transthoracic echocardiography
Lasso di tempo: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and at months 1, 2, 3, 6, 9, 12 and 15
|
|
|
Change from baseline in E/e' ratio assessed by transthoracic echocardiography
Lasso di tempo: Baseline and months 1, 2, 3, 6, 9, 12 and 15
|
Baseline and months 1, 2, 3, 6, 9, 12 and 15
|
|
|
Prescribed mavacamten dose (mg)
Lasso di tempo: Day 1 and months 1, 2, 3, 6, 9, 12 and 15
|
Day 1 and months 1, 2, 3, 6, 9, 12 and 15
|
|
|
Prescribed mavacamten maintenance dose (mg) during follow-up
Lasso di tempo: Up to 15 months
|
Up to 15 months
|
|
|
Number of participants reaching mavacamten maintenance dose
Lasso di tempo: Up to 15 months
|
Up to 15 months
|
|
|
Number of participants whose prescribed mavacamten dose changed during the observation period
Lasso di tempo: Day 1 and and up to 15 months
|
Day 1 and and up to 15 months
|
|
|
Time (days) from Index Date to achieving mavacamten maintenance dose
Lasso di tempo: Day 1 and up to 15 months
|
Day 1 and up to 15 months
|
|
|
Number of participants that discontinued mavacamten treatment
Lasso di tempo: Up to 15 months
|
Up to 15 months
|
|
|
Time (days) from Index Date to mavacamten discontinuation
Lasso di tempo: Day 1 and up to 15 months
|
Day 1 and up to 15 months
|
|
|
Duration of mavacamten treatment during follow-up
Lasso di tempo: Day 1 and up to 15 months
|
Day 1 and up to 15 months
|
|
|
Prior hypertrophic cardiomyopathy (oHCM) medication drug class
Lasso di tempo: Baseline and up to 15 months
|
Drug class of background oHCM medications, including beta-blockers and calcium channel blockers |
Baseline and up to 15 months
|
|
Prior hypertrophic cardiomyopathy (oHCM) medication dose
Lasso di tempo: Baseline and up to 15 months
|
Dose of background oHCM medications, including beta-blockers and calcium channel blockers |
Baseline and up to 15 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Bristol-Myers Squibb, Bristol-Myers Squibb
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CV027-1262
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .